ALZN · Alzamend Neuro, Inc.
Alzamend Neuro Inc (ALZN)
What's happening
- ALZN is up 3.03% today, trading at $1.70. — Live quote
- Volume today (1,943) is well below its 3-month average of 127,340. (Finnhub fundamentals)
- Reports earnings on 2026-09-08, 5 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.47 actual vs. $-0.68 estimated (+31.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-09-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jan '26 | Oct '25 | Jul '25 | Jan '25 | Oct '24 |
|---|---|---|---|---|---|
| Market cap | $8.0M | $8.7M | $4.7M | $6.1M | $5.3M |
| P/E | -1.16 | -1.42 | -0.77 | -1.01 | -0.67 |
| Price/Book | 3.65 | 1.98 | 0.88 | 1.76 | 1.42 |
| ROE | -315.54% | -139.56% | -113.75% | -175.02% | -210.62% |
| ROA | -171.75% | -119.89% | -96.07% | -144.60% | -157.84% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-08-31; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -32.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ALZN
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jan '26 | Oct '25 | Jul '25 | Jan '25 | Oct '24 | Jul '24 | Jan '24 | Oct '23 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$2.2M | -$998.1K | -$2.7M | -$1.0M | -$1.4M | -$962.4K | -$2.7M | -$2.9M |
| Net income | -$2.2M | -$1.0M | -$2.7M | -$1.0M | -$1.4M | -$974.4K | -$2.7M | -$2.9M |
| EPS (diluted) | $-0.58 | $-0.30 | $-1.28 | $-1.75 | $-3.61 | $-11.42 | $-3.77 | $-4.43 |
| EPS (basic) | $-0.58 | $-0.30 | $-1.28 | $-1.75 | $-3.61 | $-11.42 | $-3.77 | $-4.43 |
Balance sheet
| Line item | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $2.1M | $4.0M | $5.1M | $6.3M | $4.6M | $4.2M | $5.0M | $1.7M |
| Total liabilities | $1.3M | $1.9M | $717.5K | $983.3K | $634.8K | $725.9K | $1.3M | $2.9M |
| Stockholders' equity | $733.2K | $2.2M | $4.4M | $5.3M | $4.0M | $3.4M | $3.8M | -$1.2M |
| Total current assets | $1.8M | $3.7M | $4.7M | $5.9M | $4.2M | $3.9M | $4.8M | $1.4M |
| Total current liabilities | — | — | — | — | — | — | — | — |
| Cash & equivalents | $710.7K | $2.7M | $4.4M | $5.6M | $3.9M | $3.4M | $4.1M | $1.2M |
| Property, plant & equipment | $314.9K | $342.6K | $370.2K | $397.9K | $425.6K | $228.3K | $241.0K | $253.7K |
| Accounts payable | — | — | — | — | — | $725.9K | $1.3M | $2.9M |
| Common stock & paid-in capital | $425 | $380 | $380 | $314 | $78 | $580 | $523 | $86 |
| Retained earnings | -$67.3M | -$64.4M | -$62.2M | -$61.2M | -$58.5M | -$57.4M | -$56.4M | -$55.0M |
Cash flow
| Line item | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.8M | -$1.7M | -$1.2M | -$2.4M | -$688.7K | -$1.4M | -$3.4M | -$1.1M |
| Investing cash flow | — | — | — | — | -$210.0K | $0 | $0 | -$90.0K |
| Financing cash flow | $794.8K | $0 | $0 | $4.0M | $1.5M | $688.7K | $6.3M | $2.0M |
| Share-based compensation | $623.8K | $9.3K | $31.5K | $42.9K | $81.3K | $81.3K | $81.3K | $81.3K |
Income statement
| Line item | Apr '26 | Apr '25 | Apr '24 | Apr '23 | Apr '22 |
|---|---|---|---|---|---|
| Operating income | -$8.8M | -$4.5M | -$9.9M | -$14.9M | -$12.3M |
| Net income | -$8.8M | -$4.5M | -$9.9M | -$14.9M | -$12.4M |
| EPS (diluted) | $-2.63 | $-11.32 | $-132.33 | $-22.89 | $-0.14 |
| EPS (basic) | $-2.63 | $-11.32 | $-132.33 | $-22.89 | $-0.14 |
Balance sheet
| Line item | Apr '26 | Jan '26 | Apr '25 | Apr '24 | Apr '23 |
|---|---|---|---|---|---|
| Total assets | $2.1M | — | $4.6M | $631.6K | $5.9M |
| Total liabilities | $1.3M | — | $634.8K | $3.2M | $2.9M |
| Stockholders' equity | $733.2K | $2.2M | $4.0M | -$2.6M | $3.0M |
| Total current assets | $1.8M | — | $4.2M | $455.2K | $5.8M |
| Total current liabilities | — | — | — | — | $2.9M |
| Cash & equivalents | $710.7K | — | $3.9M | $376.0K | $5.1M |
| Property, plant & equipment | $314.9K | — | $425.6K | $176.3K | $79.8K |
| Accounts payable | — | — | — | $2.9M | $2.9M |
| Common stock & paid-in capital | $425 | — | $78 | $8 | $65 |
| Retained earnings | -$67.3M | — | -$58.5M | -$54.0M | -$44.1M |
Cash flow
| Line item | Apr '26 | Apr '25 | Apr '24 | Apr '23 | Apr '22 |
|---|---|---|---|---|---|
| Operating cash flow | -$8.1M | -$6.6M | -$8.3M | -$8.9M | -$6.6M |
| Investing cash flow | — | -$300.0K | -$147.2K | — | -$106.5K |
| Financing cash flow | $4.8M | $10.4M | $3.7M | $200 | $18.9M |
| Share-based compensation | $707.5K | $325.1K | $955.6K | $3.6M | $4.4M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ALZN as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-03-12 to 2026-08-26
Recent transactions
- Insiders have net bought 106,388 shares over the last 182 days, across 1 purchase and 1 sale.
- Most recent: AULT MILTON C III (Reporting person) — Open market sale of 2,000 shares on 2026-08-26.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| AULT MILTON C III | Reporting person | Open market sale | 2026-08-26 | 2,000 |
| Horne William B. | Reporting person | Open market sale | 2025-12-19 | 3,333 |
| McGrath Lynne Fahey | Reporting person | Open market sale | 2025-10-23 | 30 |
| Katzoff David J | Chief Financial Officer | Open market purchase | 2025-03-21 | 5,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-26 | AULT MILTON C III | Reporting person | Open market sale | 2,000 | $1.56 |
| 2026-04-14 | AULT MILTON C III | Reporting person | Open market purchase | 108,388 | $1.00 |
| 2025-12-23 | AULT MILTON C III | Reporting person | Open market sale | 1,851 | $2.07 |
| 2025-12-19 | Horne William B. | Reporting person | Open market sale | 3,333 | $2.12 |
| 2025-10-23 | McGrath Lynne Fahey | Reporting person | Open market sale | 30 | $2.29 |
| 2025-10-09 | AULT MILTON C III | Reporting person | Open market sale | 20,397 | $2.32 |
| 2025-10-08 | AULT MILTON C III | Reporting person | Derivative conversion | 61,743 | $2.32 |
| 2025-10-08 | AULT MILTON C III | Reporting person | Open market sale | 101,394 | $2.44 |
| 2025-10-07 | AULT MILTON C III | Reporting person | Derivative conversion | 100,000 | $2.32 |
| 2025-10-07 | AULT MILTON C III | Reporting person | Open market sale | 57,379 | $2.49 |
| 2025-10-06 | AULT MILTON C III | Reporting person | Open market sale | 82,033 | $2.45 |
| 2025-10-03 | AULT MILTON C III | Reporting person | Derivative conversion | 100,000 | $2.32 |
| 2025-10-03 | AULT MILTON C III | Reporting person | Open market sale | 65,903 | $2.44 |
| 2025-10-02 | AULT MILTON C III | Reporting person | Open market sale | 20,686 | $2.39 |
| 2025-10-01 | AULT MILTON C III | Reporting person | Derivative conversion | 100,000 | $2.32 |
| 2025-10-01 | AULT MILTON C III | Reporting person | Open market sale | 36,777 | $2.35 |
| 2025-09-30 | AULT MILTON C III | Reporting person | Open market sale | 3,566 | $2.33 |
| 2025-09-29 | AULT MILTON C III | Reporting person | Open market sale | 38,324 | $2.31 |
| 2025-09-26 | AULT MILTON C III | Reporting person | Open market sale | 37,738 | $2.31 |
| 2025-09-25 | AULT MILTON C III | Reporting person | Open market sale | 14,628 | $2.31 |
| 2025-09-25 | AULT MILTON C III | Reporting person | Derivative conversion | 100,000 | $2.32 |
| 2025-09-24 | AULT MILTON C III | Reporting person | Open market sale | 39,140 | $2.31 |
| 2025-09-23 | AULT MILTON C III | Reporting person | Open market sale | 43,238 | $2.38 |
| 2025-09-22 | AULT MILTON C III | Reporting person | Derivative conversion | 100,000 | $2.32 |
| 2025-09-19 | AULT MILTON C III | Reporting person | Open market sale | 77,009 | $2.35 |
| 2025-09-18 | AULT MILTON C III | Reporting person | Open market sale | 20,870 | $2.47 |
| 2025-09-17 | AULT MILTON C III | Reporting person | Derivative conversion | 100,000 | $2.32 |
| 2025-09-17 | AULT MILTON C III | Reporting person | Open market sale | 2,121 | $2.45 |
| 2025-07-31 | AULT MILTON C III | Reporting person | Open market sale | 100,000 | $2.22 |
| 2025-07-30 | AULT MILTON C III | Reporting person | Derivative conversion | 100,000 | $2.32 |
| 2025-07-30 | AULT MILTON C III | Reporting person | Open market sale | 29,449 | $2.51 |
| 2025-07-28 | AULT MILTON C III | Reporting person | Open market sale | 8,311 | $2.68 |
| 2025-07-25 | AULT MILTON C III | Reporting person | Open market sale | 36,532 | $2.90 |
| 2025-07-24 | AULT MILTON C III | Reporting person | Open market sale | 9,621 | $2.93 |
| 2025-07-23 | AULT MILTON C III | Reporting person | Derivative conversion | 143,429 | $2.32 |
| 2025-07-23 | AULT MILTON C III | Reporting person | Open market sale | 59,516 | $2.95 |
| 2025-05-12 | AULT MILTON C III | Reporting person | Open market sale | 1,213 | $5.06 |
| 2025-05-12 | AULT MILTON C III | Reporting person | Open market sale | 11 | $5.28 |
| 2025-03-26 | Horne William B. | Reporting person | Open market purchase | 3,334 | $0.99 |
| 2025-03-21 | AULT MILTON C III | Reporting person | Open market purchase | 2,905 | $1.02 |
| 2025-03-21 | Katzoff David J | Chief Financial Officer | Open market purchase | 5,000 | $1.01 |
| 2025-03-20 | Horne William B. | Reporting person | Open market purchase | 5,000 | $0.98 |
| 2025-03-18 | Horne William B. | Reporting person | Option exercise | 10,000 | $0.06 |
| 2025-03-18 | Horne William B. | Reporting person | Open market purchase | 5,000 | $0.97 |
| 2025-03-18 | AULT MILTON C III | Reporting person | Open market purchase | 5,000 | $0.96 |
| 2025-03-12 | AULT MILTON C III | Reporting person | Open market purchase | 100 | $0.68 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 11:53 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-31 | 4 | 2026-08-26 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-07-31 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-07-31 | View on SEC.gov → |
| 2026-08-03 | 8-K | 2026-08-03 | View on SEC.gov → |
| 2026-07-22 | 10-K | 2026-04-30 | View on SEC.gov → |
| 2026-07-21 | 8-K | 2026-07-21 | View on SEC.gov → |
| 2026-04-17 | 8-K | 2026-04-17 | View on SEC.gov → |
| 2026-04-16 | 4 | 2026-04-14 | View on SEC.gov → |
| 2026-03-20 | 8-K | 2026-03-20 | View on SEC.gov → |
| 2026-03-11 | 10-Q | 2026-01-31 | View on SEC.gov → |
| 2026-03-06 | 8-K | 2026-03-06 | View on SEC.gov → |
| 2025-12-30 | 4 | 2025-12-23 | View on SEC.gov → |
Recent news
Headlines about ALZN (Alzamend Neuro, Inc.). Links open the publisher — we don’t host full articles.
-
Alzamend Neuro Files Prospectus Related To The Resale Of Up To 98.4M Common Shares By Selling Stockholder
Benzinga · 2026-08-21 -
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Yahoo · 2026-08-20 -
Alzamend Neuro Announces Its Abstract On Resting-State Functional Magnetic Resonance Imaging Findings For AL001 Accepted For Presentation At Neuroscience 2026
Benzinga · 2026-08-20 -
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
Yahoo Finance · 2026-08-18 -
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
Yahoo Finance · 2026-08-04 -
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Yahoo Finance · 2026-04-07 -
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Yahoo Finance · 2026-03-26 -
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
Yahoo Finance · 2026-03-16
No headlines in this category right now — try “All”.